Lipocalin-2 linked with inflammatory response during heart transplants.
Apr 28, 2007 - 12:14:24 PM
, Reviewed by: Dr. Rashmi Yadav
|
|
|
âThe major goal of our research activities is therefore to understand the exact mechanisms of this injury concomitant to organ transplantation.â
|
|
Key Points of this article
|
|
The identification of Lcn-2 could be a first step towards reducing this inflammatory response and increasing the success rate of heart transplants worldwide.
|
|
the study finds that Lcn-2 is released by inflammatory cells attacking transplanted hearts in mice, and suggests that the protein is responsible for attracting further inflammatory response.
|
|
|
|
By Blackwell Publishing Ltd.,
[RxPG] A new study, led by Felix Aigner, M.D., has identified a protein known as Lipocalin-2 (Lcn-2) as potentially responsible for regulating the bodyâs inflammatory response during heart transplants. One of the major complications involved with many transplantations is the damage done to the transplanted heart during and immediately following surgery, known as ischemia and reperfusion (IR). In particular, inflammatory cells infiltrate the donated heart, which then releases enzymes and other proteins that attack the transplanted tissue, and can seriously impair the viability of replacement organs and jeopardize the health of the patient. The identification of Lcn-2 could be a first step towards reducing this inflammatory response and increasing the success rate of heart transplants worldwide. The study appears in American Journal of Transplantation.
Building on earlier work, the study finds that Lcn-2 is released by inflammatory cells attacking transplanted hearts in mice, and suggests that the protein is responsible for attracting further inflammatory response. Inflammation was found to decrease dramatically in mice in which the production of Lcn-2 was genetically disabled.
The study also found elevated levels of Lcn-2 in the kidneys of mice that had undergone heart transplants, suggesting the proteinâs possible involvement in the systemic response to IR. âThe major goal of our research activities is therefore to understand the exact mechanisms of this injury concomitant to organ transplantation,â notes Aigner, stressing the value of this research to the development of new treatment options in organ transplantation.
Advertise in this space for $10 per month.
Contact us today.
|
 |
|
Subscribe to Transplantation Newsletter
|
|
|
|
About Dr. Rashmi Yadav
|
This news story has been reviewed by Dr. Rashmi Yadav before its publication on RxPG News website. Dr. Rashmi Yadav, MBBS, is a senior editor for RxPG News. In her position she is responsible for managing special correspondents and the surgery section of the website. Her areas of special interest include cardiothoracic surgery and interventional radiology.
RxPG News is committed to promotion and implementation of Evidence Based Medical Journalism in all channels of mass media including internet.
|
|
Additional information about the news article
|
The research and viewpoints expressed in the article are those of the author and do not reflect the opinions of the journal or the affiliated societies.
This study is published in the April issue of American Journal of Transplantation. Media wishing to receive a PDF of this article may contact [email protected].
Felix Aigner M.D. is a researcher in the Department of General and Transplant Surgery at Innsbruck Medical University in Austria. His research into the role of Lipocalin-2 in organ transplantation has already led to collaborations with international immunology and molecular biology facilities. He can be reached for questions at [email protected] .
The aim of the American Journal of Transplantation is the rapid publication of new high quality data in organ and tissue transplantation and the related sciences. Its scope includes organ and tissue donation and preservation; tissue injury, repair, inflammation, and aging; immune recognition, regulation, effector mechanisms, and opportunities for induction of tolerance; histocompatibility; drugs and pharmacology relevant to transplantation; graft survival and prevention of graft dysfunction and failure; clinical trials and population analyses; transplant complications; xenotransplantation; and ethical and societal issues. The sciences include relevant aspects of cell biology, medicine, surgery, pediatrics, and infectious diseases. The journal includes thoracic transplantation (heart, lung), abdominal transplantation (kidney, liver, pancreas, islets), transplantation of tissues and related topics.. For more information, please visit www.blackwell-synergy.com/loi/ajt.
Blackwell Publishing is the worldâs leading society publisher, partnering with 665 medical, academic, and professional societies. Blackwell publishes over 800 journals and has over 6,000 books in print. The company employs over 1,000 staff members in offices in the US, UK, Australia, China, Singapore, Denmark, Germany, and Japan. Blackwellâs mission as an expert publisher is to create long-term partnerships with our clients that enhance learning, disseminate research, and improve the quality of professional practice. For more information on Blackwell Publishing, please visit www.blackwellpublishing.com or www.blackwell-synergy.com.
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
